22:06 , Jun 14, 2018 |  BC Innovations  |  Translation in Brief

There’s more to MIF

In a May Science Translational Medicine study, a European-U.S. team has shown macrophage migration inhibitory factor or sCD74, a soluble form of one its receptors, could reduce the risk of acute kidney injury in cardiac...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Carolus, Alpha-1 Foundation deal

Carolus partnered with the not-for-profit's The Alpha-1 Project (TAP) Inc. subsidiary to characterize human biological samples for the presence of chemokine CC motif ligand 5 ( RANTES ; CCL5 )- platelet factor 4 ( PF4...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Financial News

Carolus completes venture financing

Carolus Therapeutics Inc. , San Diego, Calif.   Business: Inflammation, Pulmonary, Autoimmune   Date completed: 3/5/13   Type: Venture financing   Raised: $2.3 million   Investor: Square 1 Bank  ...
07:00 , Oct 1, 2012 |  BioCentury  |  Emerging Company Profile

Innovimmune: Structuring immunotherapies

Innovimmune Biotherapeutics Inc. is using structure-based drug design to develop small molecules that precisely modulate the activity of autoimmune targets that other companies are also targeting, but for which there are not yet marketed drugs....
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Acute lung injury Chemokine CC motif ligand 5 (RANTES; CCL5); platelet factor 4 (PF4; CXCL4) Human and mouse studies suggest inhibiting the CCL5-CXCL4 interaction...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Clinical News

Carolus preclinical data

In mouse models of acute lung injury, CT-2009 disrupted heteromers formed by the platelet-derived chemokines chemokine CC motif ligand 5 ( RANTES ; CCL5 ) and platelet factor 4 ( PF4 ; CXCL4 ) and...
07:00 , Jun 9, 2011 |  BC Innovations  |  Targets & Mechanisms

Short-circuiting DCs in atherosclerosis

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice. 1 Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes...
07:00 , Aug 2, 2010 |  BioCentury  |  Emerging Company Profile

Carolus: Targeting cytokines

While cytokines are known to be effective targets to treat autoimmune and inflammatory diseases, inhibiting these molecules can restrict the defensive functions of the immune system and increase a patient's susceptibility to infection. Carolus Therapeutics...
08:00 , Jan 22, 2009 |  BC Innovations  |  Cover Story

Disrupting atherosclerosis

A team of German and U.S. researchers has designed a peptide that decreases atherosclerotic lesions in mice by disrupting interactions between two platelet-derived chemokines. 1 The findings have led to the formation of Carolus Therapeutics...